I read somewhere that Dr Mak has a new drug of his own that he was bringing to CASI and thought there would be a announcement of some kind with the ENMD name change.. I may be wrong .. In any case I'm hoping there is some significant news to announced becasue their last news with 11 patients result was certainly not steller.( JMO ). I am guessing but could there be drug sales in China very soon?? If CASI will eliminate 3 to 4 years of waiting for drug approval than we should be very close.. Close in the bio tech world means years, but that kind of news is what we need. So far none of the PR is causing investors to bite.. I don't want to put the stigma on CASI that ENMD had that it can't stand good news..Lets hope CASI has some great announcements soon.
Its only the biggest change for the treatment for diabetics since Columbus. Oh sure the stock will drop and of course FDA won't approve , and oh yes you better short it now....And the Brooklyn Bridge is still for sale....It's a revolutionary treatment. Not only that , inhalers may very well become the treatment of choice for cancers and many other diseases........So the choices are hold or sell or buy more.... Me, I'm long and accumulating on dips jmo
now redshoe be nice,, i've been in and out of bldp for years.. in fact the last time i sold some months ago i think it was around $7 or $8 that i bought at $2 . That not called manipulation is it.. its called make 26k. back in few days ago. I should have sold at 11am today but did not want to be too greedy all in the same month................ hey but thanks for the thought
yep, your right,, if it looks like a snake, walks like a snake .... its still a snake.... name change means nothing. ONLY FOR NOW....hope the snake turns into a prince........lol gd lk
CASI Pharmaceuticals Inc, formerly EntreMed, Inc., incorporated in 1991, is a clinical-stage pharmaceutical company. Its drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company’s other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis.
ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. Aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. ENMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (such as breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells.
AOL does not recognize CASI. my portfolio is in aol.. yahoo come up careside and than the system goes to casi pharm.... I don't know..............
Hi retired , hope all is well...All these weeks went by and I though CASI was a different name . I don't even remember what they were but non of them said Careside...Good question, is this the one.. ENMD is still being traded and CASI won't give me a quote.. Once today is over I guessing the tree will shake out.....